Nucleis - Radiopharmaceuticals

Nucleis is a radiopharmaceutical company active in the Nuclear Medicine sector. Nucleis is a spin-off from the University of Liège (Cyclotron Research Center - Belgium) created to outsource the GMP manufacturing and distribution of PET (Positron Emission Tomography) radiopharmaceutical drugs. Nucleis is also a key partner for CMO activities. Nucleis is the MAH (Marketing Authorisation Holder) and Manufacturer of a FDG (Fludeoxyglucose (18F)) MA (Marketing Authorisation) granted in Belgium, The Netherlands, Luxembourg, France and Germany. Nucleis aims at developing a wide portfolio of diagnostic tools in order to support the emergence of innovative therapies. Nucleis is a radiopharmaceutical company, created in June 2017 and has performed a transfer of the business unit (existing team, pharmaceutical certifications, CMO contracts and dedicated manufacturing facilities) from CRC in November 2017 and benefits from over 15 years of experience. Nucleis is a spin-off from the University of Liège (CRC-Cyclotron) created to outsource the GMP manufacturing and distribution of radiopharmaceuticals drugs dedicated to Positron Emission Tomography (PET). Nucleis propose direct sales among Nuclear Medicine department, equipped with a PET-Scan, with Glucotrace (FDG) marketed in Belgium, Netherlands, Luxembourg, France and Germany and also with other drugs with an Investigational Medicine Product dossier (clinical trial).